Around the Plaque

A collaboration between the Babraham Institute and PlaqueTec will focus on developing a bespoke cell phenotyping assay (1) that will be used in conjunction with multiomics and imaging data collected in the ongoing BIOPATTERN trial (1,2). The aim? To improve our understanding of coronary artery disease (CAD) biology with a view to more personalized treatment options.

Thanks to UKRI-BBSRC Campus Collaboration Funding, the two partners will explore cellular and molecular intricacies of CAD by applying the assay to coronary artery samples collected from patients in the ongoing trial using a liquid biopsy system.

“We were delighted to be asked to design a cell phenotyping assay using spectral flow cytometry,” says Rachael Walker, Head of the Flow Cytometry Facility at Babraham. “We’re able to use our state-of-art technology and combine it with our expertise in cytometry. We’ve relished our involvement in the project and the chance to inform better treatment options for people with CAD.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe

References

1. Babraham Institute (2024). Available at: https://bitly.ws/3aTXh
2. PlaqueTec (2023). Available at: https://bitly.ws/3aSDr 

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton